Eficácia e segurança da ponte de tirofiban como alternativa à suspensão da terapia antiplaquetária dupla em pacientes submetidos à cirurgia: uma revisão sistemática
Efficacy and safety of tirofiban bridge as an alternative to suspension of dual antiplatelet therapy in patients undergoing surgery: a systematic review
Use of a tirofiban bridge is an alternative to simply withdrawing dual antiplatelet therapy prior to operating on patients at high risk of stent thrombosis and bleeding. We aimed to evaluate the efficacy and safety of this protocol in patients undergoing surgery within 12 months of a percutaneous coronary intervention involving stenting. We performed a systematic review based on searches of the PubMed, Web of Science, Cochrane, Embase, Lilacs, and Scielo databases and of the references of relevant articles on the topic. Five of the 107 studies identified were included after application of eligibility criteria and analysis of methodological quality, totaling 422 patients, 227 in control groups. Notwithstanding the limitations reported, four of the five studies included indicate that the tirofiban bridge technique is effective for reducing adverse cardiac events and is safe in terms of not interfering with the risk of hemorrhagic events or bleeding. However, randomized clinical trials are needed to provide robust evidence
1 Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155-66.
2 Baigent C, Sudlow C, Collins R, Peto R. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86.
3 De Luca L, Bellettini E, Di Maio D, et al. Oral antiplatelet therapy for secondary prevention of non-cardioembolic ischemic cerebrovascular events. J Clin Med. 2021;10(8):1721.
4 Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2016;134(10):e123-55.
5 Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;64(22):e77-137.
6 Ullrich H, Münzel T, Gori T. Coronary stent thrombosis: predictors and prevention. Dtsch Arztebl Int. 2020;117(18):320-6.
7 Alshawabkeh LI, Prasad A, Lenkovsky F, et al. Outcomes of a preoperative “bridging” strategy with glycoprotein IIb/IIIa inhibitors to prevent perioperative stent thrombosis in patients with drug-eluting stents who undergo surgery necessitating interruption of thienopyridine administration. EuroIntervention. 2013;9(2):204-11.
8 Baber U, Dangas G, Chandrasekhar J, et al. Time-Dependent Associations between actionable bleeding, coronary thrombotic events, and mortality following percutaneous coronary intervention: results from the PARIS Registry. JACC Cardiovasc Interv. 2016;9(13):1349-57.
9 van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis: the Dutch stent thrombosis registry. J Am Coll Cardiol. 2009;53(16):1399-409.
10 Kovacic JC, Lee P, Karajgikar R, et al. Safety of temporary and permanent suspension of antiplatelet therapy after drug eluting stent implantation in contemporary “real-world” practice. J Interv Cardiol. 2012;25(5):482-92.
11 Kolh P, Wijns W, Danchin N, et al. Guidelines on myocardial revascularization. Eur J Cardiothorac Surg. 2010;38(Supl. 1):S1-52.
12 Schoos M, Power D, Baber U, et al. Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. Am J Cardiol. 2019;123(5):709-16.
13 Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: Results from the PREMIER registry. Circulation. 2006;113(24):2803-9.
14 Zheng H, Ma HP, Chen L, Zhan HT, Guo H. Prethrombotic state and cardiac events in patients with coronary heart disease during noncardiac surgery. Clin Appl Thromb Hemost. 2014;20(1):84-90.
15 Bande B, Bande S, Mohite S. The hypercoagulable states in anaesthesia and critical care. Indian J Anaesth. 2014;58(5):665-71.
16 Savonitto S, Caracciolo M, Cattaneo M, De Servi S. Management of patients with recently implanted coronary stents on dual antiplatelet therapy who need to undergo major surgery. J Thromb Haemost. 2011;9(11):2133-42.
17 De Servin F. Low-dose aspirin and clopidogrel: how to act in patients scheduled for day surgery. Curr Opin Anaesthesiol. 2007;20(6):531-4.
18 Lorga AM Fo, Azmus AD, Soeiro AM, et al. Diretrizes brasileiras de antiagregantes plaquetários e anticoagulantes em cardiologia. Arq Bras Cardiol. 2013;101(3, Supl. 3):1-95.
19 Rossini R, Musumeci G, Visconti LO, et al. Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from italian cardiological, surgical and anaesthesiological societies. EuroIntervention. 2014;10(1):38-46.
20 Kristensen SD, Knuuti J. New ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management. Eur Heart J. 2014;35(35):2344-5.
21 Rodriguez A, Guilera N, Mases A, Sierra P, Oliva JC, Colilles C. Management of antiplatelet therapy in patients with coronary stents undergoing noncardiac surgery: association with adverse events. Br J Anaesth. 2018;120(1):67-76.
22 Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
23 Santos CMDC, Pimenta CADM, Nobre MRC. A estratégia PICO para a construção da pergunta de pesquisa e busca de evidências. Rev Lat Am Enfermagem. 2007;15(3):508-11.
24 Moga C, Guo B, Harstall C. Development of a quality appraisal tool for case series studies using a modified delphi technique. Edmonton: IHE Publications; 2012 [citado 2020 set 18].
25 Bona D, Aiolfi A, Picozzi S, Rubino B, Bonavina L. Operable gastric cancer diagnosed soon after implantation of a coronary drug-eluting stent: How to manage?
26 De Servi S, Morici N, Boschetti E, et al. Bridge therapy or standard treatment for urgent surgery after coronary stent implantation: Analysis of 314 patients. Vascul Pharmacol. 2016;80:85-90.
27 D’Urbano M, Barlocco F, Poli A, et al. Unplanned surgery after drug eluting stent implantation: A strategy for safe temporary withdrawal of dual oral antiplatelet therapy. J Cardiovasc Med (Hagerstown). 2008;9(7):737-41.
28 Marcos EG, Fonseca AC, Hofma SH. Bridging therapy for early surgery in patients on dual antiplatelet therapy after drug-eluting stent implantation. Neth Heart J. 2011;19(10):412-7.
29 Park SJ, Oh IY, Kim KH, et al. Minimal withdrawal of dual antiplatelet agents under the guidance of a point-of-care platelet activity assay early after drug-eluting stent implantation for surgical removal of renal cell carcinoma. Int J Cardiol. 2011;149(2):e85-7.
30 Polito MV, Asparago S, Galasso G, et al. Early myocardial surgical revascularization after ST-segment elevation myocardial infarction in multivessel coronary disease: bridge therapy is the solution? J Cardiovasc Med (Hagerstown). 2018;19(3):120-5.
31 Savonitto S, D’Urbano M, Caracciolo M, et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: A phase II study of “bridging” antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth. 2010;104(3):285-91.
32 Vlachou M, Didagelos M, Kouparanis A, Karvounis H, Ziakas A. Bridging with tirofiban during temporary withdrawal of oral antiplatelets for two major surgical procedures in high ischaemic risk patients. Open Cardiovasc Med J. 2019;13(1):1-4.
33 Walker EA, Dager WE. Bridging with tirofiban during oral antiplatelet interruption: a single-center case series analysis including patients on hemodialysis. Pharmacotherapy. 2017;37(8):888-92.
34 Xia JG, Qu Y, Shen H, Liu XH. Short-term follow-up of tirofiban as alternative therapy for urgent surgery patients with an implanted coronary drug-eluting stent after ST-elevation myocardial infarction. Coron Artery Dis. 2013;24(6):522-6.
35 Zhou L-Q, Chen S-M, Zhang Y-Z, He L-Y, Gao W. Two case of preoperative bridging therapy for patients undergoing non-cardiac surgery after coronary stent implantation. J Geriatr Cardiol. 2017;14(7):488-90.
36 Rao AK, Pratt C, Berke A, et al. Thrombolysis in myocardial infarction (TIMI) trial-Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11(1):1-11.
37 Morici N, Moja L, Rosato V, et al. Bridge with intravenous antiplatelet therapy during temporary withdrawal of oral agents for surgical procedures: a systematic review. Intern Emerg Med. 2014;9(2):225-35.
38 Schulz S, Schuster T, Mehilli J, et al. Stent thrombosis after drug-eluting stent implantation: Incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J. 2009;30(22):2714-21.
39 Burger W, Chemnitius JM, Kneissl GD, Rücker G. Low-close aspirin for secondary cardiovascular prevention - Cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation: review and meta-analysis. J Intern Med. 2005;257(5):399-414.
40 Li X, Zhang S, Wang Z, et al. Platelet function and risk of bleeding in patients with acute coronary syndrome following tirofiban infusion. Front Pharmacol. 2019;10:1158.
41 Kannel WB. Framingham study insights into hypertensive risk of cardiovascular disease. Hypertens Res. 1995;18(3):181-96.
42 Cardiac Society of Australia and New Zealand. Guidelines for the management of antiplatelet therapy in patients with coronary stents undergoing non-cardiac surgery. Heart Lung Circ. 2010;19(1):2-10.
43 Chassot PG, Delabays A, Spahn DR. Perioperative antiplatelet therapy: The case for continuing therapy in patients at risk of myocardial infarction. Br J Anaesth. 2007;99(3):316-28.